Safety and Tolerability of a Shorter Agalsidase Beta Infusion Time in Patients with Classic or Later-Onset Fabry Disease
Our results suggest that shortening the agalsidase beta infusion time to 90 min is safe and feasible in stably treated adult patients with Fabry disease and no recent infusion-associated reactions.
Authors
- Najya Bedreddine
- Liên Tran Thi Phuong
- Mihaela Țurcan
- A Vasconcelos (ORCID: https://orcid.org/0000-0002-9423-956X)
- Dominique P. Germain (ORCID: https://orcid.org/0000-0002-8355-007X)
- Wenting Trang
- Lynda Barache
Institutions
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Université Paris-Saclay (FR)
- Assistance Publique – Hôpitaux de Paris (FR)
- l'Assurance Maladie (FR)
Publication Details
- Journal
- Biomedicines
- Published
- 2024-11-11
- DOI
- https://doi.org/10.3390/biomedicines12112578
- Citations
- 1
- Primary Topic
- Lysosomal Storage Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 0.33